Albert Ferrer Olivera

Invivo Capital Partners SGEIC SA (Invivo Capital Partners) is a venture capital firm founded in 2019 by Albert Ferrer and Luis Pareras. The firm is headquartered in Barcelona, Spain.

Invivo Capital Partners SGEIC SA (Invivo Capital Partners) is a venture capital firm founded in 2019 by Albert Ferrer and Luis Pareras. The firm is headquartered in Barcelona, Spain.

Pulmobiotics SL operates as a spin off company. The firm uses its technology to discover and develop novel treatments and vaccines for respiratory diseases. The company was founded by Maria Lluch and Lluis Serrano and is headquartered in Barcelona, Spain.

Telum Therapeutics SL is a Spanish biotechnology company that specializes in drug discovery and the use of Innovative Phage Lytic Proteins as antibiotics. The company is based in Noáin, Spain. The company has specific programs to treat serious multidrug-resistant Gram-negative infections caused by Enterobacteriaceae, Acinetobacter baumannii, and Pseudomonas aeruginosa. Telum Therapeutics leverages the power of nature through the understanding of biological controls exerted by bacteriophages to balance bacterial ecosystems. The CEO of the company is Roberto Díez-Martínez.

Invivo Capital Partners SGEIC SA (Invivo Capital Partners) is a venture capital firm founded in 2019 by Albert Ferrer and Luis Pareras. The firm is headquartered in Barcelona, Spain.

Invivo Capital Partners SGEIC SA (Invivo Capital Partners) is a venture capital firm founded in 2019 by Albert Ferrer and Luis Pareras. The firm is headquartered in Barcelona, Spain.

Telum Therapeutics SL is a Spanish biotechnology company that specializes in drug discovery and the use of Innovative Phage Lytic Proteins as antibiotics. The company is based in Noáin, Spain. The company has specific programs to treat serious multidrug-resistant Gram-negative infections caused by Enterobacteriaceae, Acinetobacter baumannii, and Pseudomonas aeruginosa. Telum Therapeutics leverages the power of nature through the understanding of biological controls exerted by bacteriophages to balance bacterial ecosystems. The CEO of the company is Roberto Díez-Martínez.

GlyCardial Diagnostics SL has developed a biomarker called iSCOR that can detect cardiac ischemia through a blood test. The company is based in Barcelona, Spain. Early detection of ischemia can prevent myocardial damage. The Spanish company was founded in 2017 by Rafols Judit Cubedo, Lina Badimon Maestro, Capmany Teresa Padro, and Gemma Vilahur. Rafols Judit Cubedo has been the CEO since 2017.

GlyCardial Diagnostics SL has developed a biomarker called iSCOR that can detect cardiac ischemia through a blood test. The company is based in Barcelona, Spain. Early detection of ischemia can prevent myocardial damage. The Spanish company was founded in 2017 by Rafols Judit Cubedo, Lina Badimon Maestro, Capmany Teresa Padro, and Gemma Vilahur. Rafols Judit Cubedo has been the CEO since 2017.

Riva y García Gestión SGIIC SA (Riva y Garcia Private Equity) is a private equity and venture capital subsidiary of Grupo Financiero Riva y García SL /New/ founded in 2000 by Borja García-Nieto Portabella. It is headquartered in Barcelona, Spain.

Telum Therapeutics SL is a Spanish biotechnology company that specializes in drug discovery and the use of Innovative Phage Lytic Proteins as antibiotics. The company is based in Noáin, Spain. The company has specific programs to treat serious multidrug-resistant Gram-negative infections caused by Enterobacteriaceae, Acinetobacter baumannii, and Pseudomonas aeruginosa. Telum Therapeutics leverages the power of nature through the understanding of biological controls exerted by bacteriophages to balance bacterial ecosystems. The CEO of the company is Roberto Díez-Martínez.

Gyala Therapeutics SL develops CAR-T therapies for treating hematological malignancies. The company is based in Barcelona, Spain. Claudio Santos has been the CEO of the Spanish company since 2020.